Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Liabilities and Shareholders Equity: 2021-2024

Historic Liabilities and Shareholders Equity for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $351.2 million.

  • ARS Pharmaceuticals' Liabilities and Shareholders Equity rose 71.32% to $372.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 51.58%. This contributed to the annual value of $351.2 million for FY2024, which is 50.59% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its Liabilities and Shareholders Equity stood at $351.2 million for FY2024, which was up 50.59% from $233.2 million recorded in FY2023.
  • Over the past 5 years, ARS Pharmaceuticals' Liabilities and Shareholders Equity peaked at $351.2 million during FY2024, and registered a low of $61.4 million during FY2021.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $281.4 million (2022), whereas its average is $288.6 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first soared by 358.02% in 2022, then dropped by 17.14% in 2023.
  • Yearly analysis of 4 years shows ARS Pharmaceuticals' Liabilities and Shareholders Equity stood at $61.4 million in 2021, then surged by 358.02% to $281.4 million in 2022, then fell by 17.14% to $233.2 million in 2023, then skyrocketed by 50.59% to $351.2 million in 2024.